Alphatec Stock Gets Reduced EPS Estimate from HC Wainwright

Alphatec logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.35 per share from a loss of $0.29, while maintaining a Buy rating and a $20 price target. Its estimate is slightly more optimistic than the consensus forecast of a $0.40 loss.
  • Alphatec’s latest quarter fell short of expectations: EPS was $0.09 versus the $0.10 consensus, and revenue was $221.17 million versus estimates of $225.16 million. Revenue nevertheless rose 12.6% year over year.
  • Analyst views remain mixed: MarketBeat’s consensus rating is Moderate Buy with a $15.37 target, while shares opened at $6.94, near their 52-week low of $6.70.
  • MarketBeat previews the top five stocks to own by December 1st.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for Alphatec in a research note issued to investors on Friday, November 13th. HC Wainwright analyst S. Lee now forecasts that the medical technology company will earn ($0.35) per share for the year, down from their previous forecast of ($0.29). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Alphatec's current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Alphatec's Q4 2026 earnings at $0.02 EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $0.56 EPS, FY2029 earnings at $0.67 EPS and FY2030 earnings at $0.74 EPS.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The firm had revenue of $221.17 million for the quarter, compared to analyst estimates of $225.16 million. During the same quarter last year, the firm posted $0.03 EPS. The firm's revenue for the quarter was up 12.6% on a year-over-year basis.

A number of other research firms also recently issued reports on ATEC. Stephens started coverage on Alphatec in a research note on Thursday, July 23rd. They set an "overweight" rating and a $15.00 price target on the stock. Needham & Company LLC reduced their price objective on Alphatec from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, October 30th. BMO Capital Markets downgraded Alphatec from an "outperform" rating to a "market perform" rating and set a $8.00 price objective for the company. in a report on Friday, October 30th. Weiss Ratings lowered shares of Alphatec from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Finally, UBS Group lowered shares of Alphatec from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $15.00 to $8.50 in a research report on Wednesday, November 4th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.37.

View Our Latest Stock Analysis on ATEC

Alphatec Stock Up 2.4%

Shares of NASDAQ ATEC opened at $6.94 on Wednesday. The stock has a market cap of $1.08 billion, a PE ratio of -12.62 and a beta of 0.88. Alphatec has a 52-week low of $6.70 and a 52-week high of $23.29. The business has a 50-day moving average price of $9.65 and a 200 day moving average price of $10.08.

Institutional Investors Weigh In On Alphatec

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Alphatec by 26.9% in the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company's stock valued at $27,863,000 after acquiring an additional 543,059 shares in the last quarter. Marshall Wace LLP purchased a new position in Alphatec during the third quarter worth about $24,355,000. Penn Capital Management Company LLC raised its holdings in Alphatec by 18.9% during the third quarter. Penn Capital Management Company LLC now owns 1,769,971 shares of the medical technology company's stock worth $18,299,000 after purchasing an additional 281,911 shares in the last quarter. Aberdeen Group plc raised its holdings in Alphatec by 44.1% during the third quarter. Aberdeen Group plc now owns 1,712,328 shares of the medical technology company's stock worth $17,671,000 after purchasing an additional 523,747 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY acquired a new stake in Alphatec in the second quarter valued at about $9,413,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Transactions at Alphatec

In related news, Director David Demski purchased 60,000 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were purchased at an average price of $6.81 per share, with a total value of $408,600.00. Following the completion of the acquisition, the director directly owned 491,635 shares in the company, valued at $3,348,034.35. This represents a 13.90% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles purchased 115,000 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The stock was bought at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the transaction, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 13.48% of the company's stock.

Key Stories Impacting Alphatec

Investors following ATEC have been watching these stories:

  • Negative Sentiment: HC Wainwright cut estimates across multiple periods: Q4 2026 EPS to $0.02 from $0.07; FY2026 to a loss of $0.35 per share from $0.29; and its FY2027–FY2030 forecasts were also reduced. The wide-ranging revisions may weigh on expectations for Alphatec’s earnings growth. Alphatec analyst estimates
  • Negative Sentiment: Alphatec was reported to have hit a new 52-week low amid an analyst downgrade, reinforcing concerns about recent share-price weakness. Alphatec hits new 52-week low
  • Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of Alphatec investors. The announcement could add uncertainty, though it does not establish wrongdoing or indicate the outcome of any claim. Pomerantz investigation announcement

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company's product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Featured Articles

Earnings History and Estimates for Alphatec (NASDAQ:ATEC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alphatec Right Now?

Before you consider Alphatec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.

While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines